Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 1
1973 1
1974 1
1975 1
1976 4
1977 2
1978 5
1979 3
1980 2
1981 5
1982 1
1983 3
1984 2
1985 5
1986 6
1987 5
1988 4
1989 9
1990 14
1991 18
1992 18
1993 17
1994 21
1995 18
1996 20
1997 29
1998 23
1999 21
2000 26
2001 17
2002 22
2003 18
2004 34
2005 35
2006 29
2007 43
2008 41
2009 37
2010 47
2011 72
2012 56
2013 55
2014 58
2015 58
2016 60
2017 66
2018 66
2019 77
2020 88
2021 78
2022 64
2023 65
2024 30

Text availability

Article attribute

Article type

Publication date

Search Results

1,352 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Progressive microcephaly-seizures-cortical blindness-developmental delay syndrome"
Page 1
Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.
Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, Gitelman SE, Knecht LA, Niemoeller E, Tian W, Herold KC; PROTECT Study Investigators. Ramos EL, et al. N Engl J Med. 2023 Dec 7;389(23):2151-2161. doi: 10.1056/NEJMoa2308743. Epub 2023 Oct 18. N Engl J Med. 2023. PMID: 37861217 Clinical Trial.
BACKGROUND: Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or older with preclinical (stage 2) disease. Whether …
BACKGROUND: Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay t …
New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A, Bravo GM. Bazinet A, et al. Curr Treat Options Oncol. 2022 May;23(5):668-687. doi: 10.1007/s11864-022-00965-1. Epub 2022 Mar 23. Curr Treat Options Oncol. 2022. PMID: 35320468 Review.
Although treatment objectives in lower-risk MDS (LR-MDS) have traditionally been directed at improving cytopenias (usually anemia) as well as quality of life, recent data supports a potential role for early intervention in delaying transfusion dependency. In addition, care …
Although treatment objectives in lower-risk MDS (LR-MDS) have traditionally been directed at improving cytopenias (usually anemia) as well a …
Therapies in Stiff-Person Syndrome: Advances and Future Prospects Based on Disease Pathophysiology.
Dalakas MC. Dalakas MC. Neurol Neuroimmunol Neuroinflamm. 2023 Apr 14;10(3):e200109. doi: 10.1212/NXI.0000000000200109. Print 2023 May. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37059468 Free PMC article. Review.
If not properly treated or untreated because of delayed diagnosis, SPS progresses leading to disability; it is therefore fundamental to apply the best therapeutic schemes from the outset. This article is focused on the rationale of specific therapeutic strategies ba …
If not properly treated or untreated because of delayed diagnosis, SPS progresses leading to disability; it is therefore funda …
How we manage adults with myelodysplastic syndrome.
Fenaux P, Platzbecker U, Ades L. Fenaux P, et al. Br J Haematol. 2020 Jun;189(6):1016-1027. doi: 10.1111/bjh.16206. Epub 2019 Sep 30. Br J Haematol. 2020. PMID: 31568568 Free article. Review.
The prognosis in Myelodysplastic syndromes (MDS), although recently refined by molecular studies, remains largely based on conventional prognostic scores [International Prognostic Scoring System (IPSS), revised IPSS], classifying patients into "lower risk" MDS (LR-MDS) and …
The prognosis in Myelodysplastic syndromes (MDS), although recently refined by molecular studies, remains largely based on convention …
Maternal fever in labor: etiologies, consequences, and clinical management.
Goetzl L. Goetzl L. Am J Obstet Gynecol. 2023 May;228(5S):S1274-S1282. doi: 10.1016/j.ajog.2022.11.002. Epub 2023 Mar 20. Am J Obstet Gynecol. 2023. PMID: 36997396 Review.
A recent, double-blind randomized trial of nulliparas at >36 weeks' gestation demonstrated that a high-dose oxytocin regimen (66 mU/min) when compared with a low-dose oxytocin regimen (22 mU/min) led to clinically meaningful reductions in the rate of intrapartum …
A recent, double-blind randomized trial of nulliparas at >36 weeks' gestation demonstrated that a high-dose oxytocin regime …
Prone position in acute respiratory distress syndrome. Rationale, indications, and limits.
Gattinoni L, Taccone P, Carlesso E, Marini JJ. Gattinoni L, et al. Am J Respir Crit Care Med. 2013 Dec 1;188(11):1286-93. doi: 10.1164/rccm.201308-1532CI. Am J Respir Crit Care Med. 2013. PMID: 24134414 Review.
Over the last 15 years, five major trials have been conducted to compare the prone and supine positions in acute respiratory distress syndrome, regarding survival advantage. The sequence of trials enrolled patients who were progressively more hypoxemic; exposure to …
Over the last 15 years, five major trials have been conducted to compare the prone and supine positions in acute respiratory distress syn …
Treadmill interventions in children under six years of age at risk of neuromotor delay.
Valentín-Gudiol M, Mattern-Baxter K, Girabent-Farrés M, Bagur-Calafat C, Hadders-Algra M, Angulo-Barroso RM. Valentín-Gudiol M, et al. Cochrane Database Syst Rev. 2017 Jul 29;7(7):CD009242. doi: 10.1002/14651858.CD009242.pub3. Cochrane Database Syst Rev. 2017. PMID: 28755534 Free PMC article. Review.
BACKGROUND: Delayed motor development may occur in children with Down syndrome, cerebral palsy, general developmental delay or children born preterm. ...OBJECTIVES: To assess the effectiveness of treadmill interventions on locomotor development in children wi …
BACKGROUND: Delayed motor development may occur in children with Down syndrome, cerebral palsy, general developmental delay …
Tardive syndromes.
Mulroy E, Balint B, Bhatia KP. Mulroy E, et al. Pract Neurol. 2020 Oct;20(5):368-376. doi: 10.1136/practneurol-2020-002566. Epub 2020 Jun 2. Pract Neurol. 2020. PMID: 32487722 Review.
Dopamine receptor-blocking antipsychotics, first introduced into clinical practice in 1952, were hailed as a panacea in the treatment of a number of psychiatric disorders. ...Although tardive syndromes have been an important part of movement disorder clinical …
Dopamine receptor-blocking antipsychotics, first introduced into clinical practice in 1952, were hailed as a panacea in the treatment …
Treatment of MDS.
Platzbecker U. Platzbecker U. Blood. 2019 Mar 7;133(10):1096-1107. doi: 10.1182/blood-2018-10-844696. Epub 2019 Jan 22. Blood. 2019. PMID: 30670446 Free article. Review.
The heterogeneous nature of myelodysplastic syndromes (MDS) demands a complex and personalized variety of therapeutic approaches. ...These approaches are noncurative and aimed instead at improving cytopenias and quality of life and delaying disease progres …
The heterogeneous nature of myelodysplastic syndromes (MDS) demands a complex and personalized variety of therapeutic approaches. ... …
Dialysis-related amyloidosis.
Dzido G, Sprague SM. Dzido G, et al. Minerva Urol Nefrol. 2003 Jun;55(2):121-9. Minerva Urol Nefrol. 2003. PMID: 12847416 Review.
This review focuses on the chemical modifications of beta(2)-microglobulin that lead to the formation and deposition of beta(2)-amyloid fibrils in periarticular and articular sites which ultimately results in the clinical and radiographic characteristics of this devastatin …
This review focuses on the chemical modifications of beta(2)-microglobulin that lead to the formation and deposition of beta(2)-amyloid fibr …
1,352 results